Table 3.

Unadjusted efficacy outcomes.

	Fingolimod (N = 271)		Dimethyl fumarate (N = 342)
	N or mean	% or SD	N or mean	% or SD	p value
Patients with a relapse during first two years of study drug	24	8.9%	44	12.9%	0.116
MRI available while on drug in first two years	214	79.0%	260	76.0%	0.387
Mean number of available MRIs	1.64	0.69	1.63	0.68	0.895
Patients with contrast enhancement	28	13.1%	26	10.0%	0.293
Patients with new T2 lesions	75	35.1%	82	31.5%	0.419
Composite efficacy measurea	94	34.7%	115	33.6%	0.783

^aPatients who had a clinical relapse, contrast enhancement or a new T2 lesion on follow-up MRI.

MRI: magnetic resonance imaging.